Boston Scientific's Q2 Earnings Coming Up: Buy, Hold or Sell the Stock?

BSX faces Q2 results with growth expected in key businesses, but lowered full-year guidance, cost pressures and weak stock performance cloud the outlook.

Zacks Investment Research • Jul 21, 2026

Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know

Boston Scientific (BSX) reached $43.19 at the closing of the latest trading day, reflecting a -1.33% change compared to its last close.

Zacks Investment Research • Jul 21, 2026

Artisan Value Fund Q2 2026 Portfolio Update

US equities advanced during Q2, supported by another quarter of better-than-expected corporate earnings and continued enthusiasm for companies benefiting from artificial intelligence-related investment. Our bottom five contributors to return in Q2 were Accenture, CME Group, Salesforce, Boston Scientific and EOG Resources. Our top five contributors to return in Q2 were Texas Instruments, Lam Research, NXP Semiconductors, Elevance Health and Alphabet.

Seeking Alpha • Jul 21, 2026

Parnassus Growth Equity Fund Q2 2026 Portfolio Activity

Twist Bioscience provides exposure to two powerful long-term trends in Health Care, AI-supported drug discovery and next-generation sequencing. Lumentum offers exposure to a key bottleneck in AI infrastructure, optical networking, as rising data demand drives a shift away from copper-based systems. Insmed's thesis had largely played out following positive TPIP data and upward revisions to Brinsupri sales.

Seeking Alpha • Jul 17, 2026

Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note

In the latest trading session, Boston Scientific (BSX) closed at $42.63, marking a -4.52% move from the previous day.

Zacks Investment Research • Jul 14, 2026

Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks Investment Research • Jul 10, 2026

Billionaire Steve Cohen Sold Amazon and Nvidia but Loaded Up on This Beaten-Down Stock

Amazon and Nvidia have been caught up in the AI trade, but have flatlined so far in 2026. Steve Cohen's Point72 Asset Management sold Amazon and Nvidia in the first quarter.

The Motley Fool • Jul 9, 2026

'Selling Winners, Buying Losers': Tech Stocks Drop as Energy Jumps to Start H2

A sharp rotation trade has taken over markets to start the second half of 2026, with investors dumping the year's biggest winners and piling into beaten-down names.

Benzinga • Jul 9, 2026

Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts

Boston Scientific (BSX) closed at $44.6 in the latest trading session, marking a -1.2% move from the prior day.

Zacks Investment Research • Jul 6, 2026

Boston Scientific: The Time Has Come To Catch This Falling Knife

Relative to its all-time high of $109.50 reached in September 2025, Boston Scientific Corporation's share price has declined by almost 60% to trade at around $45.00 per share. To put my money where my mouth is, I purchased my last shares on June 30th at an average price of $42.83. My overall purchase price now stands at $45.52. As part of its Q1-26 earnings, Boston Scientific announced a significant outlook revision, reducing its organic growth guidance for fiscal 2026 to a range between 6.5% and 8.0%.

Seeking Alpha • Jul 6, 2026